|
20 Sep 2025 |
Aurobindo Pharma
|
Consensus Share Price Target
|
1119.20 |
1293.39 |
- |
15.56 |
buy
|
|
|
|
|
13 Feb 2024
|
Aurobindo Pharma
|
BOB Capital Markets Ltd.
|
1119.20
|
1100.00
|
1026.40
(9.04%)
|
Target met |
Hold
|
|
|
Q3 EBITDA/PAT surged 68%/90% YoY led by growth in US/EM revenue and ~700bps jump in operating margin
|
|
17 Nov 2023
|
Aurobindo Pharma
|
Geojit BNP Paribas
|
1119.20
|
1037.00
|
1007.35
(11.10%)
|
Target met |
Hold
|
|
|
|
|
13 Nov 2023
|
Aurobindo Pharma
|
Axis Direct
|
1119.20
|
1080.00
|
979.35
(14.28%)
|
Target met |
Buy
|
|
|
ABRP has several growth levers in place. These are 1) Generic injectibles, Eugia ($520 Mn sales) that could grow by low double-digit growth based on value-added approval, 2) The launch of Trastzumab biosimilars in 2FY24E
|
|
11 Nov 2023
|
Aurobindo Pharma
|
Prabhudas Lilladhar
|
1119.20
|
1065.00
|
979.70
(14.24%)
|
Target met |
Accumulate
|
|
|
|
|
23 Aug 2023
|
Aurobindo Pharma
|
Geojit BNP Paribas
|
1119.20
|
915.00
|
838.85
(33.42%)
|
Target met |
Hold
|
|
|
|
|
18 Aug 2023
|
Aurobindo Pharma
|
Axis Direct
|
1119.20
|
1000.00
|
857.80
(30.47%)
|
Target met |
Buy
|
|
|
Company Outlook & Guidance: ABRP has several growth levers in place. These are 1) Generic injectibles, Eugia ( Euro 411 Mn sales) that could grow by low double-digit growth based on value-added approval.
|
|
15 Aug 2023
|
Aurobindo Pharma
|
ICICI Securities Limited
|
1119.20
|
920.00
|
871.65
(28.40%)
|
Target met |
Accumulate
|
|
|
Aurobindo’s Q1 performance was driven largely by traction in regulated markets. Lower export incentives exerted a 50bps impact on EBITDA margin, which otherwise at 16.8% would have been better than expected. US sales crossed a milestone of USD 400mn after a gap of two years.
|
|
15 Aug 2023
|
Aurobindo Pharma
|
BOB Capital Markets Ltd.
|
1119.20
|
880.00
|
871.65
(28.40%)
|
Target met |
Hold
|
|
|
Q1 revenue/EBITDA beat consensus by 4%/9% with adj. PAT (ex-one-off charge) running 15% ahead
|
|
14 Aug 2023
|
Aurobindo Pharma
|
Prabhudas Lilladhar
|
1119.20
|
900.00
|
871.65
(28.40%)
|
Target met |
Accumulate
|
|
|
|
|
14 Aug 2023
|
Aurobindo Pharma
|
Motilal Oswal
|
1119.20
|
910.00
|
871.65
(28.40%)
|
Target met |
Neutral
|
|
|
|